

PB 13 of 2022

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2022 (No. 2)

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated 28 February 2022

NIKOLAI TSYGANOV

Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Contents

C 0111011		
1	Name	1
2	Commencement	1
3	Authority	1
4	•	
Schedule	1—Amendments	2
N	ational Health (Continued Dispensing - Emergency Measures) Determination 2020	2

1 Name

- (1) This instrument is the *National Health (Continued Dispensing Emergency Measures) Amendment Determination 2022 (No. 2).*
- (2) This instrument may also be cited as PB 13 of 2022.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information							
Column 1	Column 2	Column 3					
Provisions	Commencement	Date/Details					
1. The whole of this instrument	1 March 2022	1 March 2022					

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 89A(3) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

[1] Schedule 1, entry for Cefotaxime

omit:

Powder for injection 2 g (as sodium) Injection

[2] Schedule 1, after entry for Chorionic gonadotrophin in the form Injection set containing powder for injection 1,500 units, 3 and solvent 1 mL, 3

insert:

Injection set containing powder for injection 1,500 units, 3 and solvent 1 mL, 3 (s19A)

Injection

[3] Schedule 1, after entry for Etanercept in the form Injection 50 mg in 1 mL single use auto-injector, 4

insert:

Injection 50 mg in 1 mL single use dose-dispenser cartridges, 4

Injection

[4] Schedule 1, entry for Methotrexate

substitute:

	Tablet 10 mg	Oral
	Tablet 2.5 mg	Oral
	Injection 50 mg in 2 mL vial	Injection
	Injection 5 mg in 2 mL vial	Injection
	Injection 25 mg in 0.5 mL pre-filled syringe	Injection
	Injection 20 mg in 0.4 mL pre-filled syringe	Injection
	Injection 15 mg in 0.3 mL pre-filled syringe	Injection
	Injection 10 mg in 0.2 mL pre-filled syringe	Injection
Methotrexate	Injection 7.5 mg in 0.15 mL pre-filled syringe	Injection

[5] Schedule 1, after entry for Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose

insert:

Zanubrutinib	Capsule 80 mg		Oral	
--------------	---------------	--	------	--